HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CAM JAPAN HDG

28.800

0.000

Volume:- -

Turnover:- -

Market Cap:1.85B

PE:- -

High:28.800

Open:28.800

Low:28.800

Close:28.800

52wk High:30.853

52wk Low:16.832

Shares:64.20M

HK Float Shares:21.50M

Volume Ratio:- -

T/O Rate:- -

Dividend:0.33

Dividend Rate:1.15%

ROE:--

ROA:--

PB:--

PE(LYR):- -

PS:- -

Loading ...

Overview Company News Filings

Press Release: Peijia Medical Announces 2025 Annual Results

Press Release: Upbound Group, Inc. Declares Quarterly Cash Dividend of $0.39 for the Second Quarter of 2026

Press Release: Buda Juice Reports Full Year Fiscal 2025 Financial Results

Press Release: Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update

Press Release: Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights

Ericsson Signs Multi-Year 5G Core Deal With SoftBank

MT Newswires Live

Toyota Tsusho to Shift Automotive Parts Operations to Wholly Owned Subsidiary

Press Release: Archrock Announces Retirement of Chief Financial Officer Doug Aron

Press Release: SIR Royalty Income Fund Announces Filing of SIR Corp. Fiscal 2026 Second Quarter Results

Press Release: Devonian Health Group Inc. Reports Financial and Operating Results of its Three and Six Months Ended January 31, 2026

Press Release: Caliber Reports Fourth Quarter and Full Year 2025 Results

Press Release: Precigen Reports Full Year 2025 Financial Results and Business Updates

Press Release: SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Press Release: Outlook Therapeutics Announces Closing of $5.0 Million Public Offering

Press Release: Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Press Release: XtalPi Holdings Announces Full Year 2025 Annual Results

Press Release: EQB welcomes Daniel Rethazy as EVP, Personal Banking, adding top banking talent to reignite core business growth and execute on transformation

Press Release: Go Green Global Technologies Corp. Appoints Water Technology Innovator Grant Page as Chairman of the Board

Press Release: QT Imaging Reports 2025 Fourth Quarter and Full Year Financial Results

Press Release: Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/03160/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"03160","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"03160\",,,,,undefined,":{"symbol":"03160","market":"HK","secType":"STK","nameCN":"CAM JAPAN HDG","latestPrice":28.8,"timestamp":1775610013005,"preClose":28.8,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":21500000,"shares":64200000,"eps":0,"marketStatus":"Pre-opening","change":0,"latestTime":"04-08 09:15:04","open":28.8,"high":28.8,"low":28.8,"amount":0,"amplitude":0,"askPrice":29.6,"askSize":800,"bidPrice":27.14,"bidSize":2800,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1775611800000},"marketStatusCode":1,"adr":0,"listingDate":1455724800000,"exchange":"SEHK","adjPreClose":28.8,"sharesOutstanding":32400000,"nav":28.9985,"aum":690018436.003,"dividendRate":0.011458,"bidAskSpread":0,"openAndCloseTimeList":[[1775611800000,1775620800000],[1775624400000,1775635200000]],"volumeRatio":0,"lotSize":200,"spreadScale":3,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"03160\",,,,,undefined,":{"symbol":"03160","floatShares":21500000,"roa":"--","roe":"--","lyrEps":0,"shares":64200000,"dividePrice":0.33,"high":28.8,"amplitude":0,"preClose":28.8,"low":28.8,"week52Low":16.832,"pbRate":"--","week52High":30.853,"institutionHeld":0,"latestPrice":28.8,"committee":0.555556,"eps":0,"divideRate":0.011458,"volume":0,"delay":0,"ttmEps":0,"open":28.8,"prevYearClose":26.457,"fiveDayClose":28.228,"twentyDayClose":28.904,"sixtyDayClose":27.85},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/03160\",params:#limit:5,,,undefined,":[{"date":"2026-04-01","symbol":"03160","amount":0.15,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"HK","newRecordDate":"2026-04-02","defaultRemindTime":1775007000000,"name":"华夏日股对冲","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-10","payableDate":"2026-04-02","currency":"HKD","dateTimestamp":1774972800000,"payDate":"2026-04-10"},{"date":"2025-10-02","symbol":"03160","amount":0.18,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"HK","newRecordDate":"2025-10-03","defaultRemindTime":1759368600000,"name":"华夏日股对冲","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-10","payableDate":"2025-10-03","currency":"HKD","dateTimestamp":1759334400000,"payDate":"2025-10-10"},{"date":"2025-04-01","symbol":"03160","amount":0.15,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"HK","newRecordDate":"2025-04-02","defaultRemindTime":1743471000000,"name":"华夏日股对冲","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-08","payableDate":"2025-04-02","currency":"HKD","dateTimestamp":1743436800000,"payDate":"2025-04-08"},{"date":"2024-10-03","symbol":"03160","amount":0.15,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"HK","newRecordDate":"2024-10-04","defaultRemindTime":1727919000000,"name":"华夏日股对冲","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-10-10","payableDate":"2024-10-04","currency":"HKD","dateTimestamp":1727884800000,"payDate":"2024-10-10"},{"date":"2024-04-03","symbol":"03160","amount":0.12,"announcedDate":null,"type":"dividend","market":"HK","newRecordDate":"2024-04-05","defaultRemindTime":1712107800000,"name":"华夏日股对冲","recordDate":"2024-04-12","payableDate":"2024-04-05","currency":"HKD","dateTimestamp":1712073600000,"payDate":"2024-04-12"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"03160\",market:\"HK\",,,undefined,":[{"executeDate":"2017-03-30","recordDate":"2017-03-31","paymentDate":"2017-04-07","value":0.08,"currency":"HKD"},{"executeDate":"2017-09-28","recordDate":"2017-09-29","paymentDate":"2017-10-06","value":0.04,"currency":"HKD"},{"executeDate":"2018-03-28","recordDate":"2018-03-29","paymentDate":"2018-04-09","value":0.08,"currency":"HKD"},{"executeDate":"2018-10-02","recordDate":"2018-10-03","paymentDate":"2018-10-09","value":0.09,"currency":"HKD"},{"executeDate":"2019-04-01","recordDate":"2019-04-02","paymentDate":"2019-04-09","value":0.07,"currency":"HKD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"03160\",market:\"HK\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"03160\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622457852","title":"Press Release: Peijia Medical Announces 2025 Annual Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2622457852","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622457852?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:00","pubTimestamp":1774526400,"startTime":"0","endTime":"0","summary":"SUZHOU, China, March 26, 2026 /PRNewswire/ -- Peijia Medical , a leading Chinese domestic company in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced its annual results for the year ended December 31, 2025 on March 25, 2026.While maintaining a relatively stable gross margin, the Group continued to strengthen cost discipline and improve operating efficiency, supported by scale expansion and more focused resource allocation. Excluding the losses attributable to the entities comprising the Future Technology Business ([1]) , the Group's adjusted loss for the year narrowed by 44.1% year on year to RMB110.5 million, reflecting a clear trend of improving underlying profitability.The Group maintained its leading position in China's TAVR market and continued to expand its commercialization footprint. During the year, revenue from TAVR-related products increased by 11.6% year on year to RMB290.1 million. Total implant volume reached approximatel","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK4604","BK1100","BK4232","R","BK4022","BK4555","BK4588","BK4585","BK1574","BK4099","TM","03160","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622851538","title":"Press Release: Upbound Group, Inc. Declares Quarterly Cash Dividend of $0.39 for the Second Quarter of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2622851538","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622851538?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:00","pubTimestamp":1774522800,"startTime":"0","endTime":"0","summary":"Upbound Group, Inc.  , a technology and data-driven leader in accessible and inclusive financial solutions that address the evolving needs and aspirations of underserved consumers, today announced that its Board of Directors has approved a quarterly cash dividend of $0.39 for the second quarter of 2026. The dividend will be paid on April 28, 2026, to the Company's common stockholders of record as of the close of business on April 7, 2026.Upbound Group, Inc. , is a technology and data-driven leader in accessible and inclusive financial solutions that address the evolving needs and aspirations of underserved consumers. The Company's customer-facing operating units include industry-leading brands such as Acima, Brigit, and Rent-A-Center that facilitate consumer transactions across a wide range of store-based and digital channels in the United States, Mexico and Puerto Rico. Upbound Group, Inc. is headquartered in Plano, Texas. For additional information about the Company, please visit our","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","R","BK4604","BK4022","BK4555","BK4099","BK4200","TM","UPBD","BK4232","03160","BK4076","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622851309","title":"Press Release: Buda Juice Reports Full Year Fiscal 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2622851309","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622851309?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:00","pubTimestamp":1774522800,"startTime":"0","endTime":"0","summary":"Profitable Ultra Fresh Platform Delivered Double-Digit Revenue Growth, Strong Margins and Free Cash Flow in Fiscal 2025. January 2026 IPO Strengthened Balance Sheet to Support Growth Initiatives. Buda Juice, Inc. , $BUDA, creator and pioneer of the Ultra Fresh category in the supermarket fresh perimeter, today reported financial results for the year ended December 31, 2025.Horatio Lonsdale-Hands, Co-Founder and Chief Executive Officer of Buda Juice, commented:. \"Fiscal 2025 was an important year for Buda Juice. We delivered double-digit revenue growth, remained profitable, generated free cash flow, and completed our IPO in January 2026.\"Our business continues to be built on the strength of our Ultra Fresh platform. Through our Fresh35deg cold chain, we produce, package, and deliver products cold, without pasteurization, HPP, or other processing.Buda Juice  is the creator and pioneer of the Ultra Fresh category through an end-to-end cold chain platform that delivers always-cold, freshly","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BUDA","TM","03160","BK4099","BK4604","BK4555","BK4212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622518778","title":"Press Release: Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2622518778","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622518778?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:00","pubTimestamp":1774522800,"startTime":"0","endTime":"0","summary":"BETHESDA, Md., March 26, 2026  -- Gain Therapeutics, Inc.  , a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the fourth quarter and year ended December 31, 2025, and provided a corporate update.Mr. Mack continued, \"We will continue to follow patients in the Phase 1b nine-month extension study that is expected to complete in September 2026 and look forward to presenting longer-term follow up at additional scientific conferences throughout the balance of the year. To date, MDS-UPDRS scores remained stable and durable across the overall study population after 150 days of treatment with GT-02287 and are becoming more encouraging with the passage of time. We believe the totality of the data continues to support the potential of GT-02287 in both idiopathic and GBA1 Parkinson's disease and we hope to one day shift the treatment paradigm away from symptomatic relief ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","BK4023","GT","BK4585","BK4139","GANX","IND","BK4232","BK4588","R","BK4604","03160","LU1169590202.USD","CSF","DDC","BK4212","BK4022","BK4555","BK4119","BK4099","LU1169589451.USD","TM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622077859","title":"Press Release: Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2622077859","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622077859?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:00","pubTimestamp":1774522800,"startTime":"0","endTime":"0","summary":"-- Expect to report topline results for ALTITUDE-AD, a Phase 2 study to. investigate sabirnetug  for the treatment of early Alzheimer's. -- Lead clinical candidate IND filing in Acumen's Enhanced Brain Delivery. and $35.75 million private placement to advance candidates in. -- Cash, cash equivalents and marketable securities of $116.9 million as of. NEWTON, Mass., March 26, 2026  --  Acumen Pharmaceuticals, Inc.  , a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers  for the treatment of Alzheimer's disease , today reported financial results for the full year ended December 31, 2025 and provided a business update.to advance candidates in its A<BETA>O-selective EBD portfolio, following. four poster presentations at the International Conference on Alzheimer's","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4132","BK4232","BK4585","BK4588","03160","BETA","BK4139","BK4187","BK4555","BK4604","IND","R","TM","BK4539","BK4099","AD","ABOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622837649","title":"Ericsson Signs Multi-Year 5G Core Deal With SoftBank","url":"https://stock-news.laohu8.com/highlight/detail?id=2622837649","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622837649?lang=en_us&edition=fundamental","pubTime":"2026-03-26 16:29","pubTimestamp":1774513765,"startTime":"0","endTime":"0","summary":"Ericsson  said Thursday it has signed a multi-year framework agreement with SoftBank to deploy next-generation core network solutions in Japan to modernize infrastructure and accelerate adoption of standalone 5G.The company said the agreement covers its dual-mode 5G core running on its cloud-native infrastructure, along with subscriber data management, policy control, and IP multimedia systems.The deployment will support SoftBank's shift to 5G standalone while integrating existing 4G and 5G services, to improve network scalability and reliability, it added.It also includes upgrades to subscriber data management and modernization of voice and multimedia systems.Ericsson said the project will help enable faster rollout of new services, while automation and cloud-based operations are expected to streamline processes and reduce costs.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4591","BK4554","03160","SFTBY","BK4132","BK4515","ERIC","BK4020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622832636","title":"Toyota Tsusho to Shift Automotive Parts Operations to Wholly Owned Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2622832636","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622832636?lang=en_us&edition=fundamental","pubTime":"2026-03-26 15:55","pubTimestamp":1774511714,"startTime":"0","endTime":"0","summary":"An announcement from Toyota Tsusho ( ($JP:8015) ) is now available. Toyota Tsusho will transfer a portion of its domestic automotive parts business...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/toyota-tsusho-to-shift-automotive-parts-operations-to-wholly-owned-subsidiary?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/toyota-tsusho-to-shift-automotive-parts-operations-to-wholly-owned-subsidiary?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["03160","BK4555","BK4588","TM","BK4099","BK4604","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622889339","title":"Press Release: Archrock Announces Retirement of Chief Financial Officer Doug Aron","url":"https://stock-news.laohu8.com/highlight/detail?id=2622889339","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622889339?lang=en_us&edition=fundamental","pubTime":"2026-03-26 08:58","pubTimestamp":1774486680,"startTime":"0","endTime":"0","summary":"HOUSTON, March 25, 2026  -- Archrock, Inc.   today announced that Douglas S. Aron, Senior Vice President and Chief Financial Officer, has informed the Company of his intention to retire by the end of 2026 or when a successor is named. The Company has engaged an executive search firm to assist with the identification and evaluation of potential successors.\"Doug has been a valued partner and critical member of our leadership team during a period when Archrock has transformed its business and meaningfully improved its balance sheet and profitability,\" said Brad Childers, President and Chief Executive Officer. \"We are grateful for his many contributions and are well prepared for the next chapter with a strong leadership team and clear strategy in place,\" concluded Childers.\"I want to thank the Board, Brad, and the incredibly talented team across Archrock for their trust, partnership, and commitment over the last eight years,\" said Aron. \"As I look ahead, I am committed to helping Archrock ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","BK4604","03160","TM","BK4179","BK4585","AROC","BK4555","BK4588","VDE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622007545","title":"Press Release: SIR Royalty Income Fund Announces Filing of SIR Corp. Fiscal 2026 Second Quarter Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2622007545","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622007545?lang=en_us&edition=fundamental","pubTime":"2026-03-26 05:00","pubTimestamp":1774472400,"startTime":"0","endTime":"0","summary":"-- Food and beverage revenue from corporate restaurant operations increased. by 4.0% to $68.1 million, compared to $65.5 million for the 12-week. -- Consolidated Same Store Sales  increased by 0.5%.-- On December 3, 2025, SIR opened a new Jack Astor's Bar & Grill (\"Jack. Astor's\") location in Oshawa, Ontario that includes its new concept,Freida's Beverage Kitchen . This Jack Astor's + Freida's. location is expected to be added to the Royalty Pooled Restaurants (the. -- Effective January 1, 2026, the new Scaddabush Italian Kitchen & Bar.  location in Barrie, Ontario was added to the Royalty. Pooled Restaurants, and the closed Jack Astor's location in Longueuil,Quebec was removed. The Royalty Pool currently consists of 52 restaurants,including: 35 Jack Astor's restaurants, 14 Scaddabush locations, REDS. Square One, The Loose Moose Tap + Grill and Edna + Vita.Same Store Sales   12-WeekPeriod EndedFebruary 15,2026  12-WeekPeriod EndedFebruary 9,  Variance  24-WeekPeriod EndedFebruary 15,20","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4588","03160","BK4232","BK4585","BK4099","BK4555","R","TM","BK4604","SIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622028940","title":"Press Release: Devonian Health Group Inc. Reports Financial and Operating Results of its Three and Six Months Ended January 31, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2622028940","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622028940?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:23","pubTimestamp":1774470180,"startTime":"0","endTime":"0","summary":"-- Quarter ended January 31, 2026, net loss of $2.2 million dollars, . -- Six months ended January 31, 2026, net loss of $3.8 million dollars,-- Thykamine radiodermatitis prevention pivotal clinical study as a. -- Company continues preclinical studies for Thykamine in MASH and. Fibrosis, furthering the understanding of Thykamine's mechanism of. Following the expiry of the Altius Healthcare LP  distribution agreements, the Company is transitioning toward a focused biopharmaceutical development strategy centered on Thykamine. The Company is actively evaluating strategic alternatives for the Altius business while pursuing financing options to support its pipeline.Metabolic dysfunction--associated steatotic liver disease progresses to metabolic dysfunction-associated steatohepatitis , which features inflammation, hepatocellular bloating, and subsequent worsening of fibrosis. If left untreated, MASH can progress to cirrhosis of the liver and hepatocellular carcinoma, liver failure, and deat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","BK4022","BK4588","BK4555","BK4099","03160","R","DVHGF","BK4007","BK4585","BK4232","TM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622004292","title":"Press Release: Caliber Reports Fourth Quarter and Full Year 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2622004292","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622004292?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:15","pubTimestamp":1774469700,"startTime":"0","endTime":"0","summary":"SCOTTSDALE, Ariz., March 25, 2026  -- Caliber , a diversified real estate and digital asset management platform, today reported results for the fourth quarter and full year ended December 31, 2025. Caliber enters 2026 with a streamlined platform and a clear path toward revenue growth and profitability, driven by the expected execution of project-level financings and continued capital formation activities.-- Platform revenue of $4.0 million, compared to $4.6 million. -- Asset management revenue of $4.0 million drove the stated results. -- Platform net loss of $7.7 million, or $1.24 per diluted share, compared. to Platform net loss of $11.6 million, or $10.34 per diluted share. -- Results largely impacted by $5.1 million unrealized loss in. Caliber's LINK treasury, driven by the change in fair value of. -- Platform Adjusted EBITDA loss of $0.4 million, compared to Platform. 31, 2024, with originations of $26.5 million, partially offset by return. -- Caliber's digital asset treasury held ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4115","BK4099","BK4135","BK4555","BK4561","BK4588","BK4532","BK4585","BK4590","BK4604","BK4144","CHT","03160","CWD","TM","BK4581","ET"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622046100","title":"Press Release: Precigen Reports Full Year 2025 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2622046100","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622046100?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:05","pubTimestamp":1774469100,"startTime":"0","endTime":"0","summary":"-- Precigen transitioned to a commercial stage company with the US approval. FDA-approved treatment for adults with RRP, in August 2025. -- PAPZIMEOS generated $3.4 million in net product revenue in the fourth. quarter of 2025, reflecting the first partial quarter of US commercial. sales as payer policies came into effect; the US launch continues to. build strong momentum, with a significant increase in demand in the first. J-code, J3404, to PAPZIMEOS, effective April 1, 2026, streamlining the. -- Marketing Authorization Application for PAPZIMEOS for the treatment of. physicians in the field of RRP recommended PAPZIMEOS as the new standard. \"Commercialization of PAPZIMEOS continues to move rapidly, with growing physician adoption and patient uptake since approval in August. Sinc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4139","BK4604","BK4202","BK4099","BK4588","BK4022","BK4232","BK4555","03160","LABU","PGEN","TM","NCI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622004619","title":"Press Release: SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2622004619","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622004619?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:05","pubTimestamp":1774469100,"startTime":"0","endTime":"0","summary":"Added top-rated children's hospitals to QUELIMMUNE pediatric Acute Kidney Injury  customer base. Completed enrollment in FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry. Exceeded 50% enrollment milestone in pivotal trial of SCD therapy in adult patients with AKI. Advanced pipeline indications with initiation of cardio-renal clinical trial. DENVER, March 25, 2026  -- SeaStar Medical Holding Corporation , a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months and year ended December 31, 2025, and provided business updates on key initiatives.\"In 2025, we broadened our customer base of top-ranked children's hospitals, continued enrollment in the NEUTRALIZE-AKI pivotal clinical trial, and advanced our pipeline with the initiation of the cardio-renal clinical trial of our selective cytopheretic device  therapy,\" said Eric Schlorff, CEO of S","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","BK4588","03160","IE00B7SZL793.SGD","ICU","BK4187","LABU","IE00B66KJ199.SGD","IE00B19Z4B17.USD","BK4099","IE0031619046.USD","SCD","TM","LU2065731478.USD","CRS","LU0963586101.USD","BK4604","BK4006","BK4585","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622004617","title":"Press Release: Outlook Therapeutics Announces Closing of $5.0 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2622004617","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622004617?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:05","pubTimestamp":1774469100,"startTime":"0","endTime":"0","summary":"ISELIN, N.J., March 25, 2026  -- Outlook Therapeutics, Inc. , a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the closing of its previously announced public offering of 20,000,000 shares of its common stock and accompanying warrants to purchase up to an aggregate of 20,000,000 shares of common stock. Each share of common stock and accompanying common warrant were sold together at a combined public offering price of $0.25. Each common warrant has an exercise price of $0.25 per share, is exercisable immediately and expires five years from the date of issuance.The aggregate gross proceeds of the offering were $5.0 million, before deducting placement agent fees and other offering expenses. The potential additional gross proceeds to Outlook Therapeutics from the common warrants, if fully exercised on a cash basis, will be approximately $5.0 million. No assurance can be given that any of the common wa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4604","BK4139","TM","BK4539","BK4099","03160","LENZ","OTLK","BK4555","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622048760","title":"Press Release: Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2622048760","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622048760?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:01","pubTimestamp":1774468860,"startTime":"0","endTime":"0","summary":"Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024. Emrosi generated net revenues of $14.7 million during the full-year period after its launch in early April 2025. Approximately 53,000 total prescriptions were filled for Emrosi during FY2025. Payer access for Emrosi available to over 100 million U.S. commercial lives. Company to hold conference call today at 4:30 p.m. ET. SCOTTSDALE, Ariz., March 25, 2026  -- Journey Medical Corporation  , a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the full year ended December 31, 2025.December 31, 2024. The growth was primarily driven by incremental revenue. from the launch and commercialization of Emrosi, partially offset by. continued competitive pressures on Accutane, revenue from which. -- Gross margin improve","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBIO","TM","BK4232","BK4555","BK4588","BK4099","BK4585","03160","BK4007","BK4139","DERM","R","BK4604","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622747110","title":"Press Release: XtalPi Holdings Announces Full Year 2025 Annual Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2622747110","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622747110?lang=en_us&edition=fundamental","pubTime":"2026-03-25 22:19","pubTimestamp":1774448340,"startTime":"0","endTime":"0","summary":"-- Revenues for year 2025 were RMB802.6 million, representing a. -- Net profit for year 2025 reached reached RMB 134.6 million, while. adjusted net profit amounted to RMB 258.2 million, making the Group's. first full year of profitability and making it the first profitable AI4S. -- As of December 31, 2025, the Group's total cash balance[1] amounted to. RMB 7,068.6 million. In 2026, the Group raised further net proceeds of. RMB 2,536.8 million through the issuance of new convertible bonds.-- Incubated and advanced more than five global first-in-class/best-in-class. innovative pipelines to clinical and/or IND-enabling stages, spanning. year-over-year. To date, the Group has cumulatively covered 17 of the. world's top 20 pharmaceutical companies, successfully delivering across. into molecular glues, peptides, and oligonucleotides, reinforcing its. synthesis experiments every week, enabling a fully closed-loop. Serving as the central orchestration hub of the development flywheel, a multi-a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","BK4588","BK4023","CHAT","BK4528","BK1141","BK4543","BK4551","AI","BK1617","02228","BK4232","TM","R","AGIX","BK4587","AIPO","BK4585","AIYY","BK4555","BK4604","03160","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622752400","title":"Press Release: EQB welcomes Daniel Rethazy as EVP, Personal Banking, adding top banking talent to reignite core business growth and execute on transformation","url":"https://stock-news.laohu8.com/highlight/detail?id=2622752400","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622752400?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:35","pubTimestamp":1774442100,"startTime":"0","endTime":"0","summary":"-- Mr. Rethazy will shape a more integrated Personal Banking business that. brings together the strength of EQB's consumer capabilities with the full. potential of the announced agreement to acquire PC Financial and enter a. that reflects EQB's growing scale, ambition and significance to the. TORONTO, March 25, 2026 /CNW/ - EQB Inc.  today announces Daniel Rethazy's appointment as Executive Vice President, Personal Banking. Mr. Rethazy brings deep experience in Canadian Banking to EQB that will accelerate momentum and unlock a new era of growth for the company's Personal Banking franchise, delivering a more competitive and rewarding banking experience, and a stronger and more resilient banking industry for all Canadians.\"EQB has a platform and an offering unlike anything else in Canadian banking -- and we are just getting started,\" said Daniel Rethazy, EVP, Personal Banking. \"EQB is challenging the status quo in banking and innovating at a rapid pace to deliver more choice, more value,","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4588","BK4585","EVP","R","TM","BK4209","BK4099","BK4555","03160","BK4604","BK4022","PC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622075242","title":"Press Release: Go Green Global Technologies Corp. Appoints Water Technology Innovator Grant Page as Chairman of the Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2622075242","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622075242?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:34","pubTimestamp":1774442040,"startTime":"0","endTime":"0","summary":"NEW YORK, March 25, 2026  -- Go Green Global Technologies Corp.  , a clean technology company developing advanced systems for sustainable water treatment, energy efficiency, and infrastructure optimization, today announced the appointment of Grant Page as Chairman of the Board of Directors, effective March 20, 2026.Mr. Page is a seasoned entrepreneur, engineer, and investor with a track record across company-building, private capital deployment, and strategic growth. A graduate of the United States Naval Academy with a Bachelor of Science in Mechanical Engineering, he pioneered early electrochemistry research that helped form the foundation of next-generation water treatment solutions. While serving as a U.S. Naval officer, he founded Magna Imperio Systems and scaled it into a venture-backed industry leader in desalination and treatment, achieving a reported valuation of $210 million through multiple financing rounds and commercial deployments.Go Green is at a pivotal stage where execu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GOGR","BK4604","BK4555","TM","BK4585","03160","BK4588","BK4099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622073652","title":"Press Release: QT Imaging Reports 2025 Fourth Quarter and Full Year Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2622073652","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622073652?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:00","pubTimestamp":1774440000,"startTime":"0","endTime":"0","summary":"2025 Revenue of $18.9 Million Exceeded Outlook with a Record 40 Scanners Shipped. Affirms 2026 Revenue Guidance of $39 Million from Contracted Scanner MOQs and Initial QTI Cloud Platform Revenue. Advances Transition to a SaaS- and Biomarker-Driven Medical Imaging Platform. Conference Call Begins Today at 4:30 p.m. Eastern Time. QT Imaging Holdings, Inc.  , a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today reported financial results for the three and twelve months ended December 31, 2025 and provided a business update.\"I am proud of the transformation QT Imaging achieved over the past year. In 2025 we exceeded our revenue target, increased scanner deployments, laid the foundation for our cloud SaaS platform, expanded internationally through new distribution partnerships, and significantly strengthened our balance sheet. This progress reflects disciplined execution across our commercial and product str","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4604","BK4099","QTI","03160","AMA","BK4555","UAE","BK4082","TM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622027703","title":"Press Release: Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2622027703","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622027703?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:00","pubTimestamp":1774436400,"startTime":"0","endTime":"0","summary":"Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference call today at 8:00 am EDT. Two Phase 2 proof-of-concept clinical trials evaluating MZE782 in PKU and CKD expected to initiate in 2026. Industry leader Neil Kumar, Ph.D., Founder and CEO of BridgeBio, appointed to Maze Board of Directors. Strong balance sheet with $360.0 million in cash, cash equivalents and marketable securities; expected cash runway into 2028. \"We are proud of the progress that Maze achieved in 2025 and have already carried our strong record of execution into the new year, as evidenced by today's positive topline data from our Phase 2 HORIZON trial of MZE829 in broad AMKD,\" said Jason Coloma, Ph.D., chief executive officer of Maze. \"We look forward to advancing MZE829 into a pivotal program and to initiating our two Phase 2 trials of MZE782 in PKU and CKD. As we continu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007","BK4585","BK4555","BK4588","TM","MIT","BK4099","FSGS","03160","BK4604"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}]}}